David Domzalski - 31 May 2024 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role: PRESIDENT AND CEO, Director
Signature: /s/ Mutya Harsch, attorney-in-fact for David Domzalski
Issuer symbol: VYNE
Transactions as of: 31 May 2024
Net transactions value: +$9,562
Form type: 4
Filing time: 04 Jun 2024, 16:30:24 UTC
Previous filing: 03 Apr 2024
Next filing: 03 Jul 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VYNE	Common Stock	Award	$9,562	+4,429	+0.9%	$2.16	498,589	31 May 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 31, 2024.

Content

These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 31, 2024.